CTOs on the Move

Fougera Pharmaceuticals

www.fougera.com

 
Fougera Pharmaceuticals is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Global CINRG

Global CINRG is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bellicum

Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy. We are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.

Sudmo North America

Sudmo North America is a Machesney Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XORTX

XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.